PPD has amped up the biologics capabilities at its Irish manufacturing operation, opening a new lab devoted to the development of large-molecule treatments.
X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.
PPD has signed a deal with service provider Shin Nippon Biomedical Laboratories to collaborate in Japan, pooling resources in a joint venture designed to tap the growing market for clinical research there.
X-Chem, the biotech that operates from within PPD, signed a second agreement with partner Bayer, outlicensing a second discovery-stage program.
PPD has signed a data-minded deal with the collection experts at ERT, a partnership the companies believe will help their clients conduct more efficient trials.
X-Chem, PPD's in-house biotech company, has signed a deal with the rare disease specialists at Alexion to lend out its molecular library and help discover new treatments.
PPD has expanded its relationship with eClinical outfit Medidata, combining technologies in risk-based monitoring to help sponsors use real-time safety data to make decisions on clinical trials.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
PPD is buying up the entirety of X-Chem, which operates as a biotech within a CRO, marking a vote of confidence in the continued demand for drug discovery services.
Countless clinical trials are done in by unexpectedly well-performing placebo arms, a phenomenon particularly common in psychiatric studies. PPD believes a new, proprietary trial design can substantially level the playing field, and the CRO has paid an undisclosed sum to get its hands on the technology.